Devarshi Bhattacharyya
Overview
Explore the profile of Devarshi Bhattacharyya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleeman N, Houten R, Nevitt S, Mahon J, Beale S, Boland A, et al.
Health Technol Assess
. 2024 Sep;
28(49):1-190.
PMID: 39252678
Background: Renal cell carcinoma is the most common type of kidney cancer, comprising approximately 85% of all renal malignancies. Patients with advanced renal cell carcinoma are the focus of this...
2.
Bresnahan R, Duarte R, Mahon J, Beale S, Chaplin M, Bhattacharyya D, et al.
Health Technol Assess
. 2023 Oct;
27(10):1-115.
PMID: 37839810
Background: Magnetic resonance imaging-based technologies are non-invasive diagnostic tests that can be used to assess non-alcoholic fatty liver disease. Objectives: The study objectives were to assess the diagnostic test accuracy,...
3.
Bresnahan R, Houten R, Greenhalgh J, Nevitt S, Mahon J, Beale S, et al.
Pharmacoecon Open
. 2023 May;
7(4):525-536.
PMID: 37195551
As part of the Single Technology Appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited Apellis Pharmaceuticals/Sobi to submit evidence for the clinical and cost...
4.
Drummond M, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, et al.
Value Health
. 2022 Aug;
25(8):1257-1267.
PMID: 35931428
Health technology assessment (HTA) has been growing in use over the past 40 years, especially in its impact on decisions regarding the reimbursement, adoption, and use of new drugs, devices,...
5.
Gathirua-Mwangi W, Sethi H, Afable M, Bhattacharyya D, Khan T
J Med Econ
. 2021 Sep;
24(1):1164-1172.
PMID: 34529522
Aim: To compare the cost of biweekly regimens of first-line (1L) treatments of cetuximab-folinic acid, fluorouracil, and irinotecan (FOLFIRI) panitumumab-folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients with Kirsten's rat...
6.
Aiello E, Bianculli P, Bhattacharyya D, Gunda P, Citera G
Value Health Reg Issues
. 2019 May;
20:86-94.
PMID: 31103950
Objective: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. This study assessed the cost-effectiveness of secukinumab, an interleukin-17A inhibitor, versus other biologics in PsA from the Argentinean social security...
7.
Purmonen T, Puolakka K, Bhattacharyya D, Jain M, Martikainen J
Cost Eff Resour Alloc
. 2018 Nov;
16:56.
PMID: 30479574
Objective: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland. Methods: In this semi-Markov...
8.
Mistry R, Suri G, Young K, Hettle R, May J, Brixner D, et al.
Curr Med Res Opin
. 2018 Jul;
34(12):2143-2150.
PMID: 30032697
Objectives: The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone...
9.
Mistry R, May J, Suri G, Young K, Brixner D, Oderda G, et al.
J Manag Care Spec Pharm
. 2018 May;
24(6):514-523.
PMID: 29799329
Background: U.S. regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with...